Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia
Authors:
- Cyril ŠálekCŠCyril Šálek
- Iuri MarinovIMIuri Marinov
- Czech Leukemia Study Group ‐ for Life (CELL)C(Czech Leukemia Study Group ‐ for Life (CELL)
- 22 June 2015
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 96 (3) , 276-284
Abstract
Objective: To evaluate the prognostic power of minimal residual disease (MRD) monitored by polymerase chain reaction at defined time points during early treatment in adult patients with acute lymphoblastic leukemia (ALL).Methods: Seventy‐one patients were treated according to the GMALL 07/2003 protocol and evaluated for MRD in bone marrow by specific clonal rearrangements of Ig/TCR in BCR‐ABL negative ALL or fusion gene transcript in BCR‐ABL positive ALL.Results: Three‐year overall survival (OS) was 94% in patients with BCR‐ABL negative ALL reaching complete molecular response (CMR) after the first course of chemotherapy (vs. 32% if MRD >10−4; P = 0.001). Patients with CMR prior to the start of consolidation chemotherapy at week 11 had 3‐yr OS 82% (vs. 18% if MRD >10−4; P = 0.001). Patients with BCR‐ABL positive ALL showed slower MRD dynamics. There was a trend to better OS in patients with ≥4 log reduction of BCR‐ABL transcript prior to HSCT (92% vs. 50%; P = 0.065). None of the patients with detectable MRD (both BCR‐ABL positive and negative) after HSCT survived 3 yr.Conclusion: Early MRD kinetics is an important tool for new prognostication models with direct clinical impact irrespective of standard prognostic factors in patients with BCR‐ABL negative ALL.Keywords
Funding Information
- Ministerstvo Zdravotnictví Ceské Republiky
This publication has 24 references indexed in Scilit:
- Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)Journal of Hematology & Oncology, 2013
- Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone MarrowJournal of Clinical Oncology, 2009
- Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Blood, 2009
- Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 StudyJournal of Clinical Oncology, 2009
- Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study GroupJournal of Clinical Oncology, 2009
- Prospective monitoring of BCR‐ABL1 transcript levels in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia undergoing imatinib‐combined chemotherapyBritish Journal of Haematology, 2008
- Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR dataLeukemia, 2007
- Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaBlood, 2006
- Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemiaLeukemia, 2005
- Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)Blood, 2003